Unicycive publishes corporate presentation on OLC hyperphosphatemia treatment for dialysis patients

Unicycive Therapeutics

Unicycive Therapeutics

UNCY

0.00
  • Unicycive highlighted oxylanthanum carbonate (OLC) as its lead program for hyperphosphatemia in chronic kidney disease patients on dialysis.
  • OLC NDA is under FDA review with a June 29, 2026 PDUFA date following a late-December 2025 resubmission.
  • Prior CRL cited a single deficiency tied to compliance status at a third-party manufacturing vendor; a Type A FDA meeting was held in late 2025.
  • Presentation framed hyperphosphatemia as a US market opportunity of more than $1 billion.
  • Unicycive projected cash runway into 2027 to support a potential OLC approval and launch.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.